1. Home
  2. Labeler Index
  3. Aphena Pharma Solutions - Tennessee, Llc
  4. 43353-746
  5. Product Images: Alfuzosin Hydrochloride

Product Images Alfuzosin Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Alfuzosin Hydrochloride NDC 43353-746 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Bottle Label 10mg - 43353 746 30

Bottle Label 10mg - 43353 746 30

This is a medication called Alfuzosin HCI ER, which comes in a pack of 30 tablets each, with a strength of 10mg. The NOC# 353074630 could be a reference number for the medication.*

Aphena Pharma Solutions - TN - Aphena

Aphena Pharma Solutions - TN - Aphena

Alfuzosin Hydrochloride Structural Formula - a9ef5385 3416 452b 97ac cac1b1bdb97f 01

Alfuzosin Hydrochloride Structural Formula - a9ef5385 3416 452b 97ac cac1b1bdb97f 01

Figure 1: Mean (SEM) Alfuzosin Plasma Concentration-Time Profiles After a Single Administration of Alfuzosin Hydrochloride Extended-Release Tablets 10 mg to Eight Healthy Middle-Aged Male Volunteers in Fed and Fasted States - a9ef5385 3416 452b 97ac cac1b1bdb97f 02

Figure 1: Mean (SEM) Alfuzosin Plasma Concentration-Time Profiles After a Single Administration of Alfuzosin Hydrochloride Extended-Release Tablets 10 mg to Eight Healthy Middle-Aged Male Volunteers in Fed and Fasted States - a9ef5385 3416 452b 97ac cac1b1bdb97f 02

This appears to be a graph showing the plasma concentration of Alfuzosin over time (in hours) for both fed and fasted conditions. The y-axis measures concentration in ng/mL, while the x-axis represents time in hours. It may be part of a study or research on the effects of food on the pharmacokinetics of Alfuzosin.*

Figure 2: Mean Change from Baseline in IPSS Total Symptom Score: Trial 1 - a9ef5385 3416 452b 97ac cac1b1bdb97f 03

Figure 2: Mean Change from Baseline in IPSS Total Symptom Score: Trial 1 - a9ef5385 3416 452b 97ac cac1b1bdb97f 03

Figure 3: Mean Change from Baseline in IPSS Total Symptom Score: Trial 2 - a9ef5385 3416 452b 97ac cac1b1bdb97f 04

Figure 3: Mean Change from Baseline in IPSS Total Symptom Score: Trial 2 - a9ef5385 3416 452b 97ac cac1b1bdb97f 04

Figure 4: Mean Change from Baseline in IPSS Total Symptom Score: Trial 3 - a9ef5385 3416 452b 97ac cac1b1bdb97f 05

Figure 4: Mean Change from Baseline in IPSS Total Symptom Score: Trial 3 - a9ef5385 3416 452b 97ac cac1b1bdb97f 05

Figure 5: Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 1 - a9ef5385 3416 452b 97ac cac1b1bdb97f 06

Figure 5: Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 1 - a9ef5385 3416 452b 97ac cac1b1bdb97f 06

Figure 6: Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 2 - a9ef5385 3416 452b 97ac cac1b1bdb97f 07

Figure 6: Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 2 - a9ef5385 3416 452b 97ac cac1b1bdb97f 07

This appears to be a statistical analysis of the mean change in milliliters (mLTs) for two groups receiving different treatments - a placebo group and a group receiving Alfuzosin HOI ER. There were 147 participants in the placebo group and 136 in the Alfuzosin group. The data was collected over 56 days of treatment and there was a statistically significant difference between the two groups (p<0.05). No further information is available.*

Figure 7: Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 3 - a9ef5385 3416 452b 97ac cac1b1bdb97f 08

Figure 7: Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 3 - a9ef5385 3416 452b 97ac cac1b1bdb97f 08

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.